CSF3 and type 1 diabetes mellitus: Targeted reduction of Teff infiltrating lymphocytes in addition to the transient (i.e., not prolonged or persistent) stimulation of Th1 and proinflammatory serum cytokine concentrations supports the beneficial effect (Table 2) of low-dose ATG, and to a lesser extent, ATG/G-CSF, in T1D (1, 48, 49).